Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrik Lassen

Showing results (41-50 of 159) with videos related to

Pageof 16
Sort By:
European Journal of Heart Failure|January 12, 2005
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fractionGedske Daugaard, Ulrik Lassen, Peter Bie, et al.
JCO Precision Oncology|January 23, 2023
Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World DataCarsten Bokemeyer, Noman Paracha, Ulrik Lassen, et al.
Clinical Laboratory|October 17, 2017
Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection ProtocolsLise B Ahlborn, Mette Madsen, Lars Jonson, et al.
Cancer Biomarkers : Section a of Disease Markers|January 26, 2011
Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancerKristoffer Staal Rohrberg, Birgit Guldhammer Skov, Ulrik Lassen, et al.
Plos One|July 26, 2022
Changes in key recruitment performance metrics from 2008-2019 in industry-sponsored phase III clinical trials registered at ClinicalTrials.govMette Brøgger-Mikkelsen, John Robert Zibert, Anders Daniel Andersen, et al.
Frontiers in Oncology|April 12, 2021
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer TypesVinicius Araujo B de Lima, Morten Hansen, Iben Spanggaard, et al.
BJC Reports|November 8, 2024
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancerAndreas Bjerrum, Andreas Frederik Henriksen, Ann Søegaard Knoop, et al.
Plos One|June 12, 2014
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenograftsMette K Nedergaard, Karina Kristoffersen, Signe R Michaelsen, et al.
The Oncologist|March 24, 2023
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost CalculatorAlbrecht Stenzinger, Brian Cuffel, Noman Paracha, et al.
Acta Oncologica (Stockholm, Sweden)|October 28, 2022
Late effects - the new focus of follow-upChristoffer Johansen, Annika von Heymann, Bolette S Rafn, et al.
Pageof 16

Showing results (41-50 of 159) with videos related to

Sort By:
Pageof 16
European Journal of Heart Failure|January 12, 2005
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fractionGedske Daugaard, Ulrik Lassen, Peter Bie, et al.
JCO Precision Oncology|January 23, 2023
Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World DataCarsten Bokemeyer, Noman Paracha, Ulrik Lassen, et al.
Clinical Laboratory|October 17, 2017
Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection ProtocolsLise B Ahlborn, Mette Madsen, Lars Jonson, et al.
Cancer Biomarkers : Section a of Disease Markers|January 26, 2011
Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancerKristoffer Staal Rohrberg, Birgit Guldhammer Skov, Ulrik Lassen, et al.
Plos One|July 26, 2022
Changes in key recruitment performance metrics from 2008-2019 in industry-sponsored phase III clinical trials registered at ClinicalTrials.govMette Brøgger-Mikkelsen, John Robert Zibert, Anders Daniel Andersen, et al.
Frontiers in Oncology|April 12, 2021
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer TypesVinicius Araujo B de Lima, Morten Hansen, Iben Spanggaard, et al.
BJC Reports|November 8, 2024
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancerAndreas Bjerrum, Andreas Frederik Henriksen, Ann Søegaard Knoop, et al.
Plos One|June 12, 2014
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenograftsMette K Nedergaard, Karina Kristoffersen, Signe R Michaelsen, et al.
The Oncologist|March 24, 2023
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost CalculatorAlbrecht Stenzinger, Brian Cuffel, Noman Paracha, et al.
Acta Oncologica (Stockholm, Sweden)|October 28, 2022
Late effects - the new focus of follow-upChristoffer Johansen, Annika von Heymann, Bolette S Rafn, et al.
Pageof 16